PROHIBITION PARTNERS Live makes its third appearance tomorrow and over the course of three days will feature dozens of virtual discussions and debates showcasing the rapid development of the global cannabis industry.
Each of the PPLive days has its own theme with tomorrow’s being Science, Research and Technology, Wednesday’s Policy & Reform and day three will focus on Business & Investment.
Earlier this year the London Stock Exchange opened its doors to the cannabis industry for the first time in its 320-year history.
With three companies already debuted on the market and many more to follow investment into the European cannabis space is reaching levels barely imaginable, even just a few years ago.
Global Cannabis Growth
Stephen Murphy, CEO of event organisers Prohibition Partners, says it is keen to support and encourage the continued development of a progressive and well-regulated global industry; one that is capable of delivering for patients, cannabis professionals and investors alike.
He said: “Access to capital has always been a key issue for the cannabis companies in emerging markets including Europe, however significant legislative and commercial events in the past six months have demonstrated to investors the growing maturity of the global market.
“With our events we’ve always wanted to give a platform for great entrepreneurs to access a network of global investors and advance their agenda and mission. From our events in Davos, New York, London and especially virtual gathering, Prohibition Partners LIVE we’ve witnessed some of the most important global transactions occurring.
“This May 18, we’re delighted to welcome over 1,500-plus industry professionals and our network of global investors to inspire and more importantly fund new ideas and initiatives that will shape the future of global cannabis for years to come. ”
Integral To Investment Plans
David Bonnier, founding partner of Swedish-based investment house Enexis, attended the first Cannabis Europa event hosted by Prohibition Partners in London in 2018. It made its first cannabis investment the following year and has now built a portfolio of 17 investee companies with more to follow.
He believes PPLive and similar events form an integral part of the investment matrix allowing investors an opportunity to understand the sector’s emerging trends and themes and engage with the companies and individuals developing these.
This year’s schedule has piqued his curiosity in a number of key areas. He said: “We’re interested in potential investment opportunities and understanding the direction in which the industry’s various sub-sectors are heading
“This year’s schedule looks interesting in relation to the patient access, the discussions on the minor cannabinoids and we’re looking forward to hearing more on the role blockchain will have to play.
Boris Jordan Highlight
“The Boris Jordan interview will be interesting in the helping to understand the evolution of a large, incumbent US business into Europe.
“It purchase of EMMAC is possibly the most significant cannabis deal the industry has witnessed – it wasn’t a cash-rich LP throwing its capital around, Curaleaf is a mature company that thinks smartly about its investing path.”
Mr Bonnier said Tuesday’s session on industrial hemp: Building a Hempire: Hemp & the Potential Impact on Global Markets recognises the growing role hemp has to play in the developing a low-carbon economy and indicated it is now pursuing opportunities in this space.
Leafy Tunnel is an early-stage venture capital firm investing in alternative medicines such as cannabis and psychedelics to address mental health and pain disorders.
Pharmaceutical Investment Path
It was co-founded by Nikolay Tretiyakov and Bek Muslimov, who have been investing in the cannabis industry since 2012.
Both co-founding partners Nikolay and Bek have worked together for more than a decade investing in European technology companies and venture funds including Monzo, Deliveroo, Superawesome, Hoxton Ventures, Isomer Capital, and others.
Leafy Tunnel is currently looking to invest in European cannabis and global psychedelics companies at the seed and Series A stages with the potential to become future billion-dollar category winners akin to GW Pharmaceuticals, which is in the process of being sold to Jazz Pharma for $7.2bn.
Mr Muslimov has attended previous Prohibition Partners events which helped to source attractive investment opportunities in the European cannabis space.
“These are must-attend events in the calendar. For serious investors they are a great platform in helping us understand where the market is moving and what the investment opportunities are,” he said.
Leafy Tunnel and Enexis are investors in Prohibition Holdings the parent company of Prohibition Partners with both saying one of the reasons they took a stake followed witnessing, at first hand, the professionalism of previous Cannabis Europa and PP Live events.
For further information on how to attend Prohibition Partners Live and to secure a ticket please see here.